Melanocyte protein PMEL;gp100;pmel 17
Melanoma antigen gp100 (280-288) is a synthetic peptide fragment derived from the gp100 glycoprotein, a well-characterized melanoma-associated antigen. As a nonapeptide corresponding to residues 280 through 288 of the full-length gp100 protein, it is recognized for its immunogenic properties and its role as a defined epitope in antigen presentation studies. The sequence is frequently utilized in immunological research, particularly in the context of tumor immunology and T cell epitope mapping, due to its relevance as a target for cytotoxic T lymphocyte (CTL) responses. Its biochemical features make it a valuable tool for dissecting antigen processing, peptide-MHC binding, and T cell receptor specificity within experimental systems.
Epitope mapping: Researchers employ the gp100 (280-288) peptide to delineate T cell epitopes relevant to melanoma antigens. By presenting this defined peptide to immune cells in vitro, scientists can identify and characterize CD8+ T cell populations that recognize the epitope in the context of HLA-A2 molecules. Such studies are fundamental for understanding the specificity and breadth of anti-melanoma immune responses, facilitating the identification of immunodominant regions within tumor antigens.
Antigen presentation studies: The peptide is widely used to investigate the mechanisms of antigen processing and presentation by major histocompatibility complex (MHC) class I molecules. By loading the peptide onto antigen-presenting cells, researchers can evaluate the efficiency of peptide-MHC complex formation, surface expression, and subsequent recognition by T cell receptors. These experiments provide critical insights into the cellular machinery governing immune recognition and are instrumental in optimizing antigen delivery strategies for immunological assays.
T cell activation assays: In functional immunology assays, the gp100 (280-288) peptide serves as a potent stimulus for activating antigen-specific CTLs. It is commonly used in co-culture experiments with T cells or peripheral blood mononuclear cells (PBMCs) isolated from individuals with known exposure to melanoma antigens. Measurement of cytokine release, proliferation, and cytotoxic activity in response to peptide stimulation enables precise quantification of cellular immune responses, supporting both basic research and translational studies in tumor immunology.
Peptide-MHC binding analysis: The defined sequence of this peptide allows for controlled studies of peptide binding affinity and stability with HLA-A2 and other MHC class I alleles. Quantitative binding assays using synthetic peptides elucidate the structural requirements for stable peptide-MHC interactions, informing the design of optimized epitopes for immune monitoring and vaccine development. Such analyses are essential for advancing understanding of peptide immunogenicity and the molecular determinants of antigen recognition.
Peptide-based assay development: The gp100 (280-288) fragment is frequently incorporated into standardized immunological assays, including ELISPOT, intracellular cytokine staining, and tetramer staining protocols. Its use as a positive control or reference antigen enables reliable detection of antigen-specific T cell responses in experimental systems. By providing a consistent and well-characterized target, it supports assay validation, quality control, and the development of robust immune monitoring platforms for research applications.
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More